Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 02 Mar 2023
The legal team said the jury's decision could make medics think twice before allowing the injured to return to the field.
Read Full NewsUse of immediate-release amantadine as an add-on to levodopa reduced peak-dose dyskinesia incidence in patients with early Parkinson disease, according to results from the phase 2 PREMANDYSK trial.
Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending January 16, 2026.
The therapy also received orphan drug designation from the FDA.
Phase 3 MODIFY Shows No Significant Renal Benefit With Lucerastat in Fabry Disease
HCPLive 5 Stories in Under 5: Week of 01/11
Topical Antioxidant Serum May Be Effective in Treating Atrophic Acne Scars
1.
Making informed decisions and managing regret after prostate cancer treatment
2.
CAR-T cell therapy for cancer causes 'brain fog,' study shows
3.
FDA Approves CAR-T Product Use for Myeloma Early.
4.
Rural-urban disparities seen in cervical cancer
5.
Chemicals in Sewage Sludge Fertilizer Pose Cancer Risk, EPA Says
1.
Navigating the Unknown: A Guide to Living With Hurthle Cell Thyroid Cancer
2.
AI-Powered Rehabilitation: A Game Changer for Hemophilia Management
3.
Anesthetic Techniques and Strategies in Cancer Surgery: Unveiling the Impact on Oncological Outcomes
4.
The Importance of Maintaining Normal Calcium Levels in Your Body
5.
The Bloodstream Compass: A Comparative Clinical Review of Liquid Biopsy and AI in Predictive Oncology
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Navigating the Complexities of Ph Negative ALL - Part II
2.
A Continuation to The Evolving Landscape of First-Line Treatment for Urothelial Carcinoma
3.
Updates on Standard V/S High Risk Myeloma Treatment- The Next Part
4.
Iron Deficiency Anemia: Ferric Maltol As a New Treatment Option- Summarization of the New Perspective
5.
Understanding Early Relapse in B-cell ALL: Rates, Risks, and Common Sites
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge